Bank of Montreal Can increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.3% in the 4th quarter, HoldingsChannel reports. The fund owned 290,892 shares of the medical research company’s stock after buying an additional 40,877 shares during the period. Bank of Montreal Can’s holdings in Thermo Fisher Scientific were worth $55,235,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. Amalgamated Bank grew its holdings in shares of Thermo Fisher Scientific by 57.0% in the second quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after acquiring an additional 16,308 shares in the last quarter. Mutual of America Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 2.1% in the second quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after acquiring an additional 977 shares in the last quarter. Americafirst Capital Management LLC bought a new position in shares of Thermo Fisher Scientific in the third quarter valued at approximately $876,000. State Board of Administration of Florida Retirement System grew its holdings in shares of Thermo Fisher Scientific by 0.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock valued at $101,317,000 after acquiring an additional 5,213 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $1,451,000. 86.25% of the stock is owned by institutional investors.
In other news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $191.74, for a total value of $9,587,000.00. Following the completion of the transaction, the chief executive officer now directly owns 302,577 shares of the company’s stock, valued at $58,016,113.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.49% of the stock is owned by company insiders.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. During the same period in the prior year, the company earned $2.03 earnings per share. Thermo Fisher Scientific’s revenue was up 13.9% compared to the same quarter last year. equities research analysts predict that Thermo Fisher Scientific Inc. will post 9.36 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Monday, January 15th. Stockholders of record on Friday, December 15th were issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date was Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is currently 10.19%.
Several research firms have recently issued reports on TMO. Barclays reaffirmed an “overweight” rating and issued a $215.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. Jefferies Group reissued a “hold” rating and set a $195.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price objective for the company in a report on Tuesday, October 31st. Leerink Swann reissued a “buy” rating on shares of Thermo Fisher Scientific in a report on Monday, October 30th. Finally, BTIG Research initiated coverage on Thermo Fisher Scientific in a report on Friday, January 5th. They set a “buy” rating and a $230.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $212.21.
ILLEGAL ACTIVITY WARNING: “Thermo Fisher Scientific Inc. (TMO) Stake Boosted by Bank of Montreal Can” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3146904/thermo-fisher-scientific-inc-tmo-stake-boosted-by-bank-of-montreal-can.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.